Table 1 Patients’ baseline characters HI type1 and type2.
Demographic data | (Non-HT group) N = 464 | Hemorrhagic infarction type 1, N = 73 | P-value | Hemorrhagic infarction type 2, N = 54 | P-value |
|---|---|---|---|---|---|
Gender, no, (percentage) | |||||
Male, no, (percentage) | 288.0 (62.1%) | 43.0 (58.9%) | 0.61 | 35.0 (64.8%) | 0.69 |
Age at time of presentation, median (IQR) | 61.0 (58.0–66.0) | 60.0 (55.0–66.0) | 0.40 | 60.0 (57.0–65.0) | 0.20 |
Location of infarction, no, (percentage) | |||||
Anterior circulation, no, (percentage) | 320.0 (69%) | 60.0 (82.2%) | 0.02* | 43.0 (79.6%) | 0.11 |
NIHSS at time of admission, median (IQR) | 10 (7.3–17.0) | 17.0 (14.0–20.0) | < 0.001* | 17.0 (12.0–20.0) | < 0.001* |
Door to needle time (min.), median (IQR) | 60.0 (55.0–66.0) | 55.0 (55.0–66.0) | 0.45 | 55.0 (55.0–66.0) | 0.46 |
Time of receiving IV rtPA from stroke onset (min.), median (IQR) | 174.0 (163.0–200.0) | 174.0 (164–200) | 0.48 | 175.0 (162–200) | 0.58 |
Patients on antiplatelets before stroke | |||||
Aspirin and clopidogrel | 120.0 (25.9%) | 17.0 (23.3%) | 0.64 | 12.0 (22.2%) | 0.56 |
Aspirin | 114.0 (24.6%) | 20.0 (27.4%) | 0.60 | 15.0 (27.8%) | 0.61 |
Clopidogrel | 90.0 (19.4%) | 17.0 (23.3%) | 0.44 | 14.0 (25.9%) | 0.15 |
Ticagrelor | 15.0 (3.2%) | 2.0 (2.7%) | 0.82 | 2.0 (3.7%) | 0.85 |
Patients on anticoagulants before stroke | |||||
Warfarin | 18.0 (3.9%) | 3.0 (4.1%) | 0.93 | 2.0 (3.7%) | 0.95 |
Rivaroxaban | 14.0 (3.0%) | 2.0 (3.0%) | 0.90 | 1.0 (1.9%) | 0.63 |
Apixaban | 10.0 (2.2%) | 1.0 (1.4%) | 0.66 | 0 | |
